PECAM1 and neoplasm: The tumors in particular from both treatment periods, during early tumor development and later during tumor progression, showed no significant difference in CD31 positive cells following Regorafenib treatment (Fig. 3a+c; see CD31 staining of the total pancreas in Supplementary Fig. S7A+B).